Trial Profile
A phase Ib combination trial of PU-H71 in patients with metastatic pancreatic cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Zelavespib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Samus Therapeutics
- 06 Apr 2017 New trial record
- 30 Mar 2017 According to a Samus Therapeutics media release, the US FDA has accepted an Investigative New Drug (IND) application to facilitate this trial for review. The company expects to treat the first patient in this trial in early second quarter of 2017.